Transcript
At Novo Nordisk, we are dedicated to developing treatments for patients living with serious chronic diseases. Human genetic evidence is becoming an increasingly important strategic tool in the way we conduct early drug discovery.
Through our involvement in the AGD Consortium, we have gained access to a broad and diverse collection of cohort data. This diversity is crucial for the future of drug discovery, as it enables us to better understand how genetics might differ across various population groups. Additionally, the data represents longitudinal information, allowing us to track patients throughout their lives. This comprehensive approach promises to significantly enhance our understanding of chronic diseases.
However, collecting data is only part of the process. It’s essential to have the proper guardrails in place to ensure consistency and reliability. For example, if different hospitals have their own methods of assembling data sets, it could undermine the ability to draw meaningful conclusions from the data. That’s why having a well-defined framework for data collection from the outset is critical, and the AGD Consortium has successfully provided this.
The NashBio team has been highly proactive in establishing this partnership, engaging in extensive discussions and ensuring that the most relevant answers are provided to the questions we pose. Similarly, the Illumina team has been incredibly collaborative throughout the process.
One of the key benefits of the AGD Consortium is that it allows pharmaceutical companies to communicate and collaborate on common goals, despite being different entities. Ultimately, we all share the same objective: to create life-saving drugs that benefit patients.
Looking back a few years, our ability to leverage large-scale population data was not as advanced as it is today. At the same time, analytics has made huge strides, and this has enormous potential for detecting new targets and gaining a deeper understanding of diseases. By absorbing more information than ever before, we are in a stronger position to drive future drug discovery.
In combination with the advancements in data and analytics, Novo Nordisk is well-positioned to develop more efficient drugs, with the ultimate goal of improving outcomes for patients.
